OBJECTIVE: To study the changes of @entity1200 ( @entity1200 ) in @entity409 at different stages, and the feasibility of @entity1200 in evaluating the severity of @entity409 . METHODS: Venous blood was extracted from 682 @entity1 with @entity409 , including @entity82 , @entity3619 , @entity99 , @entity99 , and 50 healthy blood donors as controls. Suspension of red cells in self-plasma was mixed with solution of @entity19 @entity189 cells. A @entity5 cell attached with 5 red cells or 2 lymphocytes/granulocytes was counted as one rosette. The adhesion rate was calculated. Serum soluble complement receptor 1 (sCR1) was measured with a newly established sandwich enzyme-linked immunosorbent assay (ELISA). The @entity3432 expressed on erythrocytes has assayed by cell-ELISA. RESULTS: The expression of @entity3432 on erythrocytes was lower among the @entity1 with @entity409 . Compared with that in healthy controls, @entity1200 decreased among the @entity1 with various @entity409 (all P < 0.01) in the order of @entity99 , @entity3619 , @entity82 @entity1 's A, @entity82 @entity1 's B, @entity82 @entity1 's C, and @entity99 . CHE and @entity865 decreased and PT increased among the @entity1 with @entity82 and @entity99 (all P < 0.05 or P < 0.01). @entity1200 was positively correlated with CHE, PT, and @entity865 in patents with @entity82 . CHE, PT and @entity865 remained at low levels while @entity1200 almost returned to its normal level in the convalescents of @entity99 . @entity3432 expressed on erythrocytes and sCR1 in serum in various @entity409 were decreased at different degrees, however, they changed significantly later than @entity1200 . Serum sCR1 significantly increased in the @entity1 with @entity82 , particularly in those in grades @entity1 's A to C. CONCLUSION: Low-cost, easy to operate and with early change and stable results, @entity1200 may be used as an important indicator to evaluate the severity of @entity409 . of CHE, PT/ @entity865 . It is an important to evaluate the severity of liver function in clinic.

[The changes and significance of red cell nature-immune-adhesion function in XXXX at different stages].

@entity1 :: ('9606', 'Species') :: ['Child', 'patients'] @entity3432 :: ('1378', 'Gene') :: ['CR1'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver diseases', 'liver disease'] @entity189 :: ('MESH:D002277', 'Disease') :: ['ascites carcinoma'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['red cells nature immune adhesion function', 'RNIAF'] @entity865 :: ('CHEBI:61432', 'Chemical') :: ['PTA'] @entity3619 :: ('MESH:D006521', 'Disease') :: ['chronic hepatitis'] @entity99 :: ('MESH:D056486', 'Disease') :: ['acute hepatitis', 'hepatitis gravis']
@entity409 :: (MESH:D008107,Disease) :: ['liver diseases']
